Choline Deficiency Does Not Cause Clinically Significant Impairment of Muscle Growth in Otherwise Healthy Adults
In otherwise healthy adults, choline deficiency causes only subclinical muscle damage (elevated creatine phosphokinase) rather than clinically significant impairment of muscle growth, with liver steatosis being the primary clinical manifestation of deficiency 1.
Evidence from Controlled Human Studies
The most definitive evidence comes from experimental choline depletion studies in healthy volunteers. When subjects were given severely restricted choline intake (50 mg/day for a 70 kg person) for up to 6 weeks, the clinical consequences were:
- Non-alcoholic liver steatosis (primary manifestation)
- Subclinical muscle damage reflected by increased creatine phosphokinase levels—not actual muscle atrophy or impaired growth 1
The key distinction here is "subclinical"—meaning biochemical changes without functional impairment or visible muscle loss. The guideline explicitly states these findings were "highly variable, partially explained by differences in age and gender" 1.
Context: Special Populations vs. Healthy Adults
The evidence shows different patterns across populations:
- Cystic fibrosis patients: Choline depletion "may result in liver, fatty acid, and muscle abnormalities" with demonstrated clinical benefit from supplementation 1
- Healthy adults: Only subclinical markers of muscle damage, not functional impairment
Recent Research on Muscle Growth and Choline
A 2023 randomized controlled trial provides nuanced findings: older adults (50-69 years) undergoing resistance training with low choline intake (0.7 mg/kg lean mass/day) showed significantly diminished gains in composite strength (19.4%) compared to medium/high intake groups (46.8-47.4%) 2. However, this addresses optimization of training adaptations in the context of resistance exercise—not baseline muscle growth or maintenance in sedentary healthy adults.
This distinction is critical: the study examined whether choline enhances training-induced muscle adaptations, not whether deficiency causes muscle wasting or impaired baseline muscle function.
Clinical Implications
For routine clinical practice:
- Choline deficiency screening is not routinely indicated in healthy adults
- Testing should be reserved for patients on home parenteral nutrition who develop unexplained liver steatosis/steatohepatitis OR subclinical muscle damage with high creatine kinase levels 1
- The guideline states "choline is not an essential nutrient" with only limited evidence suggesting 400-550 mg/day to support lipid metabolism 1
Common pitfall to avoid: Do not conflate subclinical biochemical changes (elevated CPK) with clinically significant muscle dysfunction. The former occurs with severe choline restriction, but does not translate to measurable muscle atrophy or functional impairment in otherwise healthy adults.
Physiological Role vs. Clinical Deficiency
While choline plays important roles in muscle physiology—including modulating muscle fat metabolism, protein homeostasis, inflammation, and autophagy 3—these mechanistic functions do not necessarily translate to clinically significant muscle growth impairment when choline is deficient in healthy adults eating typical diets.
The body can synthesize some choline endogenously (though insufficiently to meet all needs), and during fasting, choline can be released from membrane phospholipids, which may explain why severe clinical manifestations take weeks to develop even with extreme dietary restriction 1.
Bottom line: In otherwise healthy adults, prioritize screening and treatment for liver manifestations of choline deficiency rather than muscle-related concerns. Muscle effects are subclinical and secondary to the primary hepatic manifestations.